^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Danyelza (naxitamab-gqgk)

i
Other names: Hu3F8, Hu3F8 (GD2), Hu3F8-Fce, humanized 3F8 , humanized anti-GD2 antibody
Company:
Nobelpharma, SciClone, Takeda, Y-mAbs Therap
Drug class:
GD2 ganglioside inhibitor
2ms
Trial primary completion date
|
Danyelza (naxitamab-gqgk)
3ms
Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma (clinicaltrials.gov)
P=N/A, N=64, Recruiting, Guangzhou Women and Children's Medical Center
New trial
|
Danyelza (naxitamab-gqgk)
4ms
New P2 trial
|
carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • topotecan • Danyelza (naxitamab-gqgk) • Leukine (sargramostim)
4ms
Study of Chemoimmunotherapy for High-Risk Neuroblastoma (clinicaltrials.gov)
P1, N=48, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Phase classification: P2 --> P1 | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
Phase classification • Trial completion date • Trial primary completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
temozolomide • irinotecan • Danyelza (naxitamab-gqgk) • Leukine (sargramostim)
4ms
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma (clinicaltrials.gov)
P2, N=59, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2024 --> Jun 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
Trial completion date • Trial primary completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
Danyelza (naxitamab-gqgk)
7ms
Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma (clinicaltrials.gov)
P2, N=46, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed
|
Danyelza (naxitamab-gqgk)
9ms
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma (clinicaltrials.gov)
P1, N=85, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
Trial completion date • Trial primary completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
cyclophosphamide • Danyelza (naxitamab-gqgk)
10ms
Enrollment open
|
Danyelza (naxitamab-gqgk)
10ms
Partial Response to Naxitamab for Brain Metastasis in Neuroblastoma. (PubMed, J Pediatr Hematol Oncol)
Unexpectedly, her brain metastasis responded clinically, histologically, and by imaging to the treatment. We believe this is the first documented case of NBL of the brain responding to NAX.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
Danyelza (naxitamab-gqgk)
10ms
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma (clinicaltrials.gov)
P1/2, N=186, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2025
Trial completion date • Trial primary completion date • Combination therapy
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
cyclophosphamide • irinotecan • Danyelza (naxitamab-gqgk)
11ms
GM-CSF, G-CSF or no cytokine therapy with anti-GD2 immunotherapy for high-risk neuroblastoma. (PubMed, Int J Cancer)
This comprehensive review summarizes clinical data regarding efficacy and safety of GM-CSF, recombinant human granulocyte colony-stimulating factor (G-CSF) or no cytokine in combination with anti-GD2 monoclonal antibodies (ie, dinutuximab, dinutuximab beta or naxitamab) for immunotherapy of patients with high-risk neuroblastoma...Suboptimal efficacy outcomes with G-CSF raise concerns about its suitability as an alternative to GM-CSF as an adjuvant in immunotherapy for patients with high-risk neuroblastoma. While programs exist to facilitate obtaining GM-CSF and anti-GD2 monoclonal antibodies in regions where they are not commercially available, continued work is needed to ensure equitable therapeutic options are available globally.
Review • Journal
|
CSF2 (Colony stimulating factor 2)
|
Qarziba (dinutuximab beta) • Danyelza (naxitamab-gqgk) • Leukine (sargramostim)
11ms
Phase classification
|
HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule)
|
HER-2 negative
|
gemcitabine • Danyelza (naxitamab-gqgk) • UD TGFbetai NK cells
11ms
New P1/2 trial
|
HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule)
|
HER-2 negative
|
gemcitabine • Danyelza (naxitamab-gqgk) • UD TGFbetai NK cells
12ms
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study (clinicaltrials.gov)
P=N/A, N=7, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2023 --> Nov 2024 | Trial primary completion date: Nov 2023 --> Nov 2024
Trial completion date • Trial primary completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
Danyelza (naxitamab-gqgk)
1year
Enrollment open • Tumor mutational burden • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • CD4 (CD4 Molecule) • TGFBI (Transforming Growth Factor Beta Induced)
|
HER-2 negative
|
gemcitabine • Danyelza (naxitamab-gqgk) • UD TGFbetai NK cells
1year
Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes. (PubMed, Cancers (Basel))
We investigated the combination of humanized anti-GD2 mAb naxitamab (Hu3F8), irinotecan (I), temozolomide (T), and sargramostim (GM-CSF)-HITS-against primary resistant HR-NB. Cohort 1 had a 3-year OS of 84.8% and EFS 54.4%, which are statistically significant improvements (EFS p = 0.0041 and OS p = 0.0037) compared to cohort 2. In conclusion, naxitamab-based chemo-immunotherapy is effective against primary chemo-resistant HR-NB, increasing long-term outcomes when administered early during the course of treatment.
Journal
|
CSF2 (Colony stimulating factor 2)
|
irinotecan • Danyelza (naxitamab-gqgk) • Leukine (sargramostim)
1year
New P4 trial
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
Danyelza (naxitamab-gqgk)
1year
Study of Chemoimmunotherapy for High-Risk Neuroblastoma (clinicaltrials.gov)
P2, N=48, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
Trial completion date • Trial primary completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
temozolomide • irinotecan • Danyelza (naxitamab-gqgk) • Leukine (sargramostim)
over1year
Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors (clinicaltrials.gov)
P1, N=68, Completed, Memorial Sloan Kettering Cancer Center | Active, not recruiting --> Completed
Trial completion
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
Danyelza (naxitamab-gqgk)
over1year
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma (clinicaltrials.gov)
P2, N=59, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2023 --> Jun 2024 | Trial primary completion date: Jun 2023 --> Jun 2024
Trial completion date • Trial primary completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
Danyelza (naxitamab-gqgk)
over1year
Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab. (PubMed, Front Oncol)
Mean serum naxitamab levels pre- and post-STU (11.46 µg/ml pre-infusion; 100.95 µg/ml post-infusion) were within the range reported for SIR. The comparable pharmacokinetics of naxitamab during SIR and STU may indicate that switching to STU reduces G3 AEs without impact on efficacy.
Journal • Adverse events
|
Danyelza (naxitamab-gqgk)
over1year
Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use-Updated Outcome Report. (PubMed, Cancers (Basel))
Cox models showed only MRD as a predictor of EFS. In conclusion, consolidation with naxitamab resulted in reassuring survival rates for HR-NB patients after end-induction CR.
Journal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CSF2 (Colony stimulating factor 2)
|
MYCN amplification
|
Danyelza (naxitamab-gqgk)
over1year
Safety and efficacy of naxitamab plus modified dosing of GM-CSF for patients with high-risk neuroblastoma (HR-NB) in first complete remission (CR) or with primary refractory disease. (ASCO 2023)
Patients did not receive isotretinoin. This large experience confirms that the new schedule is safe and, despite short follow-up, appears as effective as the prior schedule.
Clinical
|
CSF2 (Colony stimulating factor 2)
|
Danyelza (naxitamab-gqgk)
over1year
REAL-WORLD DATA FROM ADVERSE EVENTS ASSOCIATED WITH NAXITAMAB TREATMENT IN THE UNITED STATES (US) (ASPHO 2023)
At time of approval, the safety of naxitamab per the USPI was evaluated across 97 patients from two open-label, single arm studies (Trials 201 and 12-230). Two years after approval, with more patients receiving naxitamab in the real-world clinical setting, SAERs indicate the safety profile for naxitamab remains consistent with adverse reactions reported in the clinical trials.
Clinical • Adverse events • Real-world evidence • Real-world
|
CSF2 (Colony stimulating factor 2)
|
Danyelza (naxitamab-gqgk)
over1year
REDUCTION IN BONE METASTASES AND CURIE SCORE IN PATIENTS TREATED WITH NAXITAMAB IN TRIAL 201 (ASPHO 2023)
Evaluation of patients with R/R HR-NB in bone treated with naxitamab+GM-CSF showed a similar ORR regardless of baseline CS (≤2 or ≥3). In patients with evaluable bone disease, naxitamab provided clinically meaningful response rates in the bone compartment and reduction in CS with an acceptable safety profile. Naxitamab+GM-CSF is an attractive therapeutic option for patients with R/R HR-NB in bone.  This study was funded by Y-mAbs Therapeutics, Inc.
Clinical
|
CSF2 (Colony stimulating factor 2)
|
Danyelza (naxitamab-gqgk)
over1year
Correlation between ARID1B gene mutation (p.A460, p.V215G) and prognosis of high-risk refractory neuroblastoma. (PubMed, Cell Biol Int)
Case 3 achieved CR after chemotherapy, surgery, metaiodobenzylguanidine, and 3F-8 (Naxitamab) immunotherapy after the initial diagnosis...ARID1B is a component protein of the SWI/SNF chromatin-remodeling complex that participates in the occurrence of a variety of tumors by regulating DNA repair and synthesis. ARID1B nucleic acid mutation (p.A460, p.V215G) in the promoter region of three children may contribute to the poor prognosis of NB children.
Journal • IO biomarker
|
ARID1B (AT-Rich Interaction Domain 1B)
|
Danyelza (naxitamab-gqgk)
almost2years
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study (clinicaltrials.gov)
P=N/A, N=7, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2022 --> Nov 2023 | Trial primary completion date: Nov 2022 --> Nov 2023
Trial completion date • Trial primary completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
Danyelza (naxitamab-gqgk)
2years
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)
P2, N=76, Recruiting, Wake Forest University Health Sciences | Not yet recruiting --> Recruiting
Enrollment open
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
Zykadia (ceritinib) • Danyelza (naxitamab-gqgk)
2years
ASSESSING PREDICTIVE VALUE OF RNA-SEQ OF B4GALNT1 AND ST8SIA1 AS BIOMARKERS OF GD2 EXPRESSION IN PEDIATRIC SARCOMAS (CTOS 2022)
Objective: GD2 is a tumor-associated ganglioside that is highly expressed in neuroblastoma and is targeted by two FDA-approved agents, dinutuximab and naxitamab. RNA expression of B4GALNT1 seemed to correlate and cluster better with known levels of GD2 expression than ST8SIA1 in neuroblastoma patients who historically have very high levels of GD2 expression via IHC. In sarcomas, MPNSTs had expression levels higher than that of even osteosarcoma which has been the center of clinical trials in sarcomas for GD2-targeted therapy. Given the response of bone disease with dinutuximab and naxitinib in pediatric patients with neuroblastoma, it suggests potential utility of treatment in sarcomas outside of neuroblastoma.
Clinical
|
B4GALNT1 (Beta-1,4-N-Acetyl-Galactosaminyltransferase 1) • GAPDH (Glyceraldehyde-3-Phosphate Dehydrogenase)
|
B4GALNT1 expression
|
Danyelza (naxitamab-gqgk) • Unituxin (dinutuximab)
2years
Enrollment change • Trial withdrawal
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
Danyelza (naxitamab-gqgk)
2years
Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors (clinicaltrials.gov)
P1, N=68, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Aug 2022 --> Aug 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
Trial completion date • Trial primary completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
Danyelza (naxitamab-gqgk)
over2years
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma (clinicaltrials.gov)
P2, N=76, Not yet recruiting, Wake Forest University Health Sciences
New P2 trial
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
Zykadia (ceritinib) • Danyelza (naxitamab-gqgk)
over2years
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma (clinicaltrials.gov)
P2, N=59, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jun 2022 --> Jun 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
Trial completion date • Trial primary completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
Danyelza (naxitamab-gqgk)
over2years
How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain. (PubMed, ESMO Open)
The team at Sant Joan de Déu Children's Hospital in Barcelona, Spain, have been using naxitamab to treat neuroblastoma under clinical trial protocols [e.g. Trial 201, and hu3F8, irinotecan, temozolomide, and sargramostim (GM-CSF) (HITS) study] and compassionate use since 2017. Adverse event management, including the use of ketamine to manage pain during anti-GD2 mAb infusions, is also discussed. We hope this will provide practical information for other health care providers considering offering this treatment.
Review • Journal
|
CSF2 (Colony stimulating factor 2)
|
temozolomide • irinotecan • Danyelza (naxitamab-gqgk) • Leukine (sargramostim)
over2years
Naxitamab and granulocyte macrophage colony stimulating factor (GM-CSF) in combination with irinotecan and temozolomide in patients with high-risk neuroblastoma with primary refractory disease or in first relapse: An international, single-arm, multicenter phase 2 trial. (ASCO 2022)
Key exclusion criteria include prior treatment with duration ≤3 wks (chemotherapy), ≤6wks (autologous stem cell transplant or therapeutic 131I-MIBG), ≤4wks (radiation therapy), or progressed while on anti-GD2; residual NB in the bone marrow only; and CNS/leptomeningeal disease in the prior 6 mo. Response rates will be assessed using the 2-sided binomial test at the 5% significance level; DoR, PFS, and OS will be estimated using Kaplan-Meier analysis. Adverse events will be graded per CTCAE.
P2 data • Combination therapy
|
CSF2 (Colony stimulating factor 2)
|
temozolomide • irinotecan • Danyelza (naxitamab-gqgk) • Azedra (iobenguane I 131)
over2years
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma (clinicaltrials.gov)
P1, N=85, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Jan 2022 --> Jan 2024 | Trial primary completion date: Jan 2022 --> Jan 2024
Trial completion date • Trial primary completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
cyclophosphamide • Danyelza (naxitamab-gqgk)
almost3years
Enrollment open
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
Danyelza (naxitamab-gqgk)
almost3years
Naxitamab: a humanized anti-glycolipid disialoganglioside (anti-GD2) monoclonal antibody for treatment of neuroblastoma. (PubMed, Drugs Today (Barc))
Initial outcomes with naxitamab are encouraging; however, future trials to maximize drug tolerance and elucidate its optimal role in neuroblastoma therapy in conjunction with other treatment strategies are needed. This review discusses the use of naxitamab in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of r/r HR NBL.
Journal • IO biomarker
|
CSF2 (Colony stimulating factor 2)
|
Danyelza (naxitamab-gqgk)
almost3years
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study (clinicaltrials.gov)
P=N/A, N=7, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Nov 2021 --> Nov 2022 | Trial primary completion date: Nov 2021 --> Nov 2022
Clinical • Trial completion date • Trial primary completion date
|
MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)
|
MYCN amplification
|
Danyelza (naxitamab-gqgk)